Fig. 5: IL-18 blockade sensitizes osteosarcoma to doxorubicin treatment. | Nature Communications

Fig. 5: IL-18 blockade sensitizes osteosarcoma to doxorubicin treatment.

From: Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion

Fig. 5

a–c HOS tumor-bearing mice were treated with saline or doxorubicin (DOX), with or without mouse recombinant (mr) IL-18BP. a Representative immunohistochemical images, showing F4/80, CD86, iNOS, CD206, and CD47 expression in serial sections of HOS tumors on day 22. Scale bar, 200 μm. b Statistical analyses of quantification of a (n = 4 mice per group). c Tumor growth of HOS cells in mice (n = 4 mice per group). Tumor volume was measured at the indicated time points. d–f Mice-bearing HOS tumors with or without IL18R1 depletion were treated with saline or doxorubicin (DOX) after tumors grew for 14 days. d Representative immunohistochemical images, showing F4/80, CD86, iNOS, CD206, and CD47 expression in serial sections of HOS tumors on day 22. Scale bar, 300 μm. e Statistical analyses of quantification of d (n = 5 mice per group). f Tumor growth of HOS cells in mice (n = 5 mice per group). Tumor volume was measured at the indicated time points. Data are shown as the mean ± SD. ns not significant. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA (b, e) or two-way ANOVA (c, f). The experiment was performed three times with similar results (a–f). See the Source Data file for the exact P values. Source data are provided as a Source Data file.

Back to article page